HPMA Copolymer-Based Nanomedicines in Controlled Drug Delivery

por Chytil, Petr, Kostka, Libor, Etrych, Tomáš
Publicado 2021

HPMA-Based Polymer Conjugates for Repurposed Drug Mebendazole and Other Imidazole-Based Therapeutics

por Studenovský, Martin, Rumlerová, Anna, Kostka, Libor, Etrych, Tomáš
Publicado 2021

Micelle-Forming Block Copolymers Tailored for Inhibition of P-gp-Mediated Multidrug Resistance: Structure to Activity Relationship

por Braunová, Alena, Kaňa, Martin, Kudláčová, Júlia, Kostka, Libor, Bouček, Jan, Betka, Jan, Šírová, Milada, Etrych, Tomáš
Publicado 2019

Structure-to-Efficacy Relationship of HPMA-Based Nanomedicines: The Tumor Spheroid Penetration Study

por Kudláčová, Júlia, Kotrchová, Lenka, Kostka, Libor, Randárová, Eva, Filipová, Marcela, Janoušková, Olga, Fang, Jun, Etrych, Tomáš
Publicado 2020

The development of a high-affinity conformation-sensitive antibody mimetic using a biocompatible copolymer carrier (iBody)

por Blažková, Kristyna, Beranová, Jana, Hradilek, Martin, Kostka, Libor, Šubr, Vladimír, Etrych, Tomáš, Šácha, Pavel, Konvalinka, Jan
Publicado 2021

HPMA Copolymer Mebendazole Conjugate Allows Systemic Administration and Possesses Antitumour Activity In Vivo

por Studenovský, Martin, Rumlerová, Anna, Kovářová, Jiřina, Dvořáková, Barbora, Sivák, Ladislav, Kostka, Libor, Berdár, Daniel, Etrych, Tomáš, Kovář, Marek
Publicado 2022

Enhanced Tumor Uptake and Penetration of Virotherapy Using Polymer Stealthing and Focused Ultrasound

por Carlisle, Robert, Choi, James, Bazan-Peregrino, Miriam, Laga, Richard, Subr, Vladimir, Kostka, Libor, Ulbrich, Karel, Coussios, Constantin-C., Seymour, Leonard W.
Publicado 2013

MCC950/CRID3 potently targets the NACHT domain of wild-type NLRP3 but not disease-associated mutants for inflammasome inhibition

por Vande Walle, Lieselotte, Stowe, Irma B., Šácha, Pavel, Lee, Bettina L., Demon, Dieter, Fossoul, Amelie, Van Hauwermeiren, Filip, Saavedra, Pedro H. V., Šimon, Petr, Šubrt, Vladimír, Kostka, Libor, Stivala, Craig E., Pham, Victoria C., Staben, Steven T., Yamazoe, Sayumi, Konvalinka, Jan, Kayagaki, Nobuhiko, Lamkanfi, Mohamed
Publicado 2019

Correction: MCC950/CRID3 potently targets the NACHT domain of wild-type NLRP3 but not disease-associated mutants for inflammasome inhibition

por Walle, Lieselotte Vande, Stowe, Irma B., Šácha, Pavel, Lee, Bettina L., Demon, Dieter, Fossoul, Amelie, Van Hauwermeiren, Filip, Saavedra, Pedro H. V., Šimon, Petr, Šubr, Vladimír, Kostka, Libor, Stivala, Craig E., Pham, Victoria C., Staben, Steven T., Yamazoe, Sayumi, Konvalinka, Jan, Kayagaki, Nobuhiko, Lamkanfi, Mohamed
Publicado 2019